Metabolic & Cardiometabolic

ezetimibe decreases LDL cholesterol (~18-20%)

In plain terms: Does ezetimibe meaningfully lower LDL cholesterol?

Strong support Metabolic & Cardiometabolic 🔬 Includes disconfirming

RefutedContestedStrong support

consensus score 0.83

Yes — ezetimibe lowers LDL by roughly 15-20% as monotherapy and adds a similar increment on top of a statin, a modest but reliable and well-documented effect.

📅 Last reviewed: 2026-07-15 ⓘ

Evidence ladder

How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."

Top evidence so far: All trials, pooled (Meta-analysis)

MechanismIn-vitroAnimalObservationalRCTMeta-analysis

How the studies fall

16 support 0 contradict 1 tested null 1 mixed · 18 sources, 15 independent groups

Cochrane agrees with us see how our grade compares ▾

Cochrane review 2018 · moderate to high (CV endpoints) Agrees with our grade

LDL lowering is described as the likely mechanism rather than being the review's primary endpoint.

“Same Cochrane ezetimibe review (CD012502.pub2): 'The cardiovascular benefit of ezetimibe might involve the reduction of LDL-C, total cholesterol and triglycerides.'”

Why we agree: we reached the same direction independently, from our own appraisal of 18 sources. Two methods landing in the same place is a stronger signal than either alone.

What is Cochrane, and why trust it?

Cochrane produces systematic reviews: instead of running a new study, they gather every trial ever done on a question, judge how well each was run, and pool the results. They take no commercial or industry funding, which is why the medical community treats their reviews as a gold standard — and why we check our own verdicts against theirs.

About Cochrane ↗ · Get involved / support ↗

Read the Cochrane review ↗

The evidence (18)

Source	Grade	Stance	Quality	Finding
White RT et al 2026 · study_type: observational	observational	supports	moderate	Retrospective cohort (TriNetX, n=6706) comparing bempedoic acid vs ezetimibe added to moderate-intensity statins found LDL-C reduction was greater with ezetimibe than with bempedoic acid (no numeric ezetimibe-only % given), despite bempedoi
Cannon CP, et al. (IMPROVE-IT) 2015 · N Engl J Med	RCT	supports	high	IMPROVE-IT: ezetimibe added to simvastatin in 18,144 post-ACS patients lowered LDL ~24% more (69→54 mg/dL) and cut CV events — outcomes proof it matters.
Inia JA et al 2026 · study_type: animal	animal	supports	moderate	APOE3-Leiden.CETP mice on a Western diet: ezetimibe monotherapy reduced non-HDL-C by 19%, and ezetimibe+obicetrapib combination reduced it by 75%, versus controls.
Tellier 2003 · Ann Cardiol Angeiol	meta-analysis	supports	moderate	Pooled data show ezetimibe monotherapy lowers LDL-C by ~19% and adds ~22% incremental LDL-C reduction on top of ongoing statin therapy.
Baigent 2011 (SHARP) venue: Lancet · Lancet	RCT	mixed	high	SHARP: simvastatin+ezetimibe in 9,270 CKD patients lowered LDL ~0.85 mmol/L and cut major atherosclerotic events 17% — combination benefit.
Khan 2019 · J Am Heart Assoc	meta-analysis	tested-null	high	Network meta-analysis of lipid therapies: ezetimibe add-on gave a consistent extra LDL reduction that tracked with proportional CV risk reduction per mmol/L.
Morrone 2012 · Atherosclerosis	meta-analysis	supports	high	Pooled analysis of 27 trials (>21,000 patients): ezetimibe added to statin lowered LDL ~15-20% more than statin alone across statin types and doses.
Catapano AL et al 2026 · study_type: RCT	RCT	supports	high	Phase 3 RCT (n=301) in statin-treated adults: ezetimibe 10mg monotherapy arm (n=50) produced a -27.8% (95% CI -32.3 to -23.4%) mean change in LDL-C from baseline over 56 days, versus -64.6% with enlicitide.
He H et al 2026 · study_type: observational	observational	supports	moderate	Propensity-matched cohort (1,452 vs 5,808) found statin+ezetimibe combination therapy produced a greater LDL-C reduction than high-intensity statin monotherapy (relative difference -10.6%, 95% CI -14.1 to -7.2%).
Knopp 2003 · Int J Clin Pract	RCT	supports	high	Pooled phase III monotherapy analysis: ezetimibe 10mg lowered LDL ~18% vs placebo in primary hypercholesterolemia — the pivotal monotherapy magnitude.
Blazing 2014 · Am Heart J	RCT	supports	high	In 18,144 post-ACS patients, adding ezetimibe to simvastatin further lowered LDL-C and modestly reduced cardiovascular events versus statin alone.
Yasmin 2025 · J Lipid Atheroscler	meta-analysis	supports	moderate	Meta-analysis of RCTs found moderate-intensity statin plus ezetimibe achieved LDL-C reduction comparable to high-intensity statin monotherapy.
Mikhailidis 2011 · Curr Med Res Opin	meta-analysis	supports	high	Meta-analysis: adding ezetimibe to a statin lowered LDL more than doubling/titrating the statin, confirming a consistent ~15-20% incremental effect.
Liu HH et al 2026 · study_type: observational	observational	supports	low	Narrative review states ezetimibe monotherapy reduces LDL-C by approximately 17.1-25.9%, with additional LDL-C reduction and improved goal attainment when added to statins.
Ballantyne 2003 · Circulation	RCT	supports	high	In 628 patients, ezetimibe added to atorvastatin gave an incremental ~12-14% LDL reduction beyond statin alone, roughly equal to tripling the statin dose.
Lu YW et al 2026 · study_type: observational	observational	supports	low	Retrospective cohort of 120 post-PCI patients on pitavastatin+ezetimibe combination; LDL-C decreased 32.54% from baseline after 12 months.
Gagné 2002 · Circulation	RCT	supports	moderate	Ezetimibe coadministered with statins lowered LDL a further ~21-25% versus statin plus placebo, including in difficult-to-treat familial hypercholesterolemia.
Abbas 2026 · Future Cardiol	meta-analysis	supports	moderate	Systematic review and meta-analysis confirmed pitavastatin-ezetimibe combination produced significantly greater LDL-C lowering than statin monotherapy.

Disagree, or know a study we missed?

We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.

📚 Suggest a study ⚑ Flag / request reclassification

Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).

Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.